Christian Hordo - Sep 1, 2021 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Signature
/s/ James J. MacDonald, Attorney-in-Fact for Christian Hordo
Stock symbol
SANA
Transactions as of
Sep 1, 2021
Transactions value $
-$101,743
Form type
4
Date filed
9/3/2021, 04:12 PM
Previous filing
Sep 1, 2021
Next filing
Sep 7, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SANA Common Stock Options Exercise $1.68K +1.13K +0.12% $1.48 975K Sep 1, 2021 Direct
transaction SANA Common Stock Sale -$28.4K -1.13K -0.12% $25.00 974K Sep 1, 2021 Direct F1, F2
transaction SANA Common Stock Sale -$75.1K -3K -0.31% $25.01 971K Sep 1, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SANA Stock Option (Right to Buy) Options Exercise $0 -1.13K -0.83% $0.00 135K Sep 1, 2021 Common Stock 1.13K $1.48 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.02, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.03, inclusive.
F4 This option began vesting on February 14, 2020, with 25% of the underlying shares becoming vested and exercisable on February 14, 2021 and the remainder of the underlying shares vesting at a rate of 1/36th per month thereafter.